Certara, Inc.CERTEarnings & Financial Report
Certara is a global leader in biopharmaceutical software and consulting services, specializing in modeling, simulation, and regulatory science solutions. It serves pharmaceutical companies, biotech firms and healthcare stakeholders across all drug development stages, helping accelerate new therapy launches, lower R&D risks and cut overall development costs.
Revenue
$94.8M
Gross Profit
N/A
Operating Profit
$2.6M
Net Profit
$-1.4M
Gross Margin
N/A
Operating Margin
2.7%
Net Margin
-1.4%
YoY Growth
10.8%
EPS
$-0.01
Certara, Inc. Q3 FY2024 Financial Summary
Certara, Inc. reported revenue of $94.8M (up 10.8% YoY) for Q3 FY2024, with a net profit of $-1.4M (up 97.2% YoY) (-1.4% margin).
Key Financial Metrics
| Total Revenue | $94.8M |
|---|---|
| Net Profit | $-1.4M |
| Gross Margin | N/A |
| Operating Margin | 2.7% |
| Report Period | Q3 FY2024 |
Certara, Inc. Annual Revenue by Year
Certara, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $418.8M).
| Year | Annual Revenue |
|---|---|
| 2025 | $418.8M |
| 2024 | $385.1M |
| 2023 | $354.3M |
| 2022 | $335.6M |
Certara, Inc. Quarterly Revenue & Net Profit History
Certara, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $106.9M | +0.8% | $-8.8M | -8.2% |
| Q4 FY2025 | $103.6M | +3.3% | $-5.9M | -5.7% |
| Q3 FY2025 | $104.6M | +10.3% | $1.5M | 1.5% |
| Q2 FY2025 | $104.6M | +12.1% | $-2.0M | -1.9% |
| Q1 FY2025 | $106.0M | +9.7% | $4.7M | 4.5% |
| Q4 FY2024 | $100.4M | +14.0% | $6.6M | 6.6% |
| Q3 FY2024 | $94.8M | +10.8% | $-1.4M | -1.4% |
| Q2 FY2024 | $93.3M | +3.2% | $-12.6M | -13.5% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $93.3M | $94.8M | $100.4M | $106.0M | $104.6M | $104.6M | $103.6M | $106.9M |
| YoY Growth | 3.2% | 10.8% | 14.0% | 9.7% | 12.1% | 10.3% | 3.3% | 0.8% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.54B | $1.54B | $1.58B | $1.56B | $1.54B | $1.54B | $1.56B | $1.50B |
| Liabilities | $496.2M | $489.8M | $516.4M | $476.7M | $472.9M | $471.0M | $493.8M | $483.3M |
| Equity | $1.04B | $1.05B | $1.06B | $1.08B | $1.07B | $1.06B | $1.06B | $1.02B |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $9.8M | $17.0M | $49.4M | $17.4M | $17.8M | $32.3M | $28.8M | $11.7M |